Cellvie included in national biotech team
Matzingen TG/Schlieren ZH - The support initiative Venturelab has nominated its Swiss National Startup Team for the biotech sector for the very first time. A total of ten startups could soon present themselves internationally. Cellvie AG is among them.
The Venturelab initiative is starting the first Venture Leaders program for the biotech sector. According to a press release, a jury has selected ten startups from a total of 70 applications for this. These are now Venture Leaders, thereby making them members of the Swiss National Startup Team. As with other sectors such as medtech, the biotech Venture Leaders will be able to present themselves internationally. Cellvie AG based in the St.GallenBodenseeArea is among their ranks.
Cellvie is a Harvard University spin-off that focuses on the development of medicines on the basis of cells, in so doing seeking to exploit the potential of mitochondria. Mitochondria are responsible for generating the majority of cellular energy. In cases where mitochondria stop functioning properly, this can lead to diseases such as Parkinson’s and Alzheimer’s or even cause heart attacks and strokes. Dr. James McCully, one of the founders of Cellvie and an Associate Professor at Boston Children’s Hospital, devised the Therapeutic Mitochondria Transfer (TMT) approach, which introduces healthy mitochondria into cells where the mitochondria are compromised. “To great effect. We can sustainably reinvigorate cells’ failing energy metabolism”, McCully states in a press release regarding a successful funding round securing more than 5 million US dollars at the start of the year.
The Swiss National Startup Team for the biotech sector is to present in front of international investors and potential partners. This includes a trip to China from September 6th to 10th, among other things. Cellvie will not only present biotech innovations from the St.GallenBodenseeArea, but also gain new knowledge and potentially also agree on collaborations for the future.